Viridian Therapeutics, Inc. (NASDAQ:VRDN) Stock Holdings Increased by Nuveen Asset Management LLC

Nuveen Asset Management LLC grew its holdings in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 198.2% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 681,012 shares of the company's stock after acquiring an additional 452,627 shares during the quarter. Nuveen Asset Management LLC owned about 0.86% of Viridian Therapeutics worth $13,055,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of VRDN. R Squared Ltd acquired a new stake in Viridian Therapeutics in the fourth quarter worth about $26,000. Foresite Capital Management VI LLC acquired a new position in Viridian Therapeutics during the 4th quarter valued at about $38,000. AlphaQuest LLC raised its position in shares of Viridian Therapeutics by 119.0% during the 4th quarter. AlphaQuest LLC now owns 2,795 shares of the company's stock worth $54,000 after buying an additional 1,519 shares in the last quarter. Summit Investment Advisors Inc. lifted its stake in shares of Viridian Therapeutics by 24.7% in the 4th quarter. Summit Investment Advisors Inc. now owns 7,646 shares of the company's stock worth $147,000 after acquiring an additional 1,516 shares during the period. Finally, Quantbot Technologies LP bought a new position in shares of Viridian Therapeutics in the fourth quarter valued at approximately $164,000.

Viridian Therapeutics Stock Performance

Shares of NASDAQ VRDN opened at $13.57 on Tuesday. The stock's fifty day simple moving average is $13.13 and its 200 day simple moving average is $16.67. The stock has a market capitalization of $1.11 billion, a price-to-earnings ratio of -3.15 and a beta of 0.57. The company has a quick ratio of 18.55, a current ratio of 18.55 and a debt-to-equity ratio of 0.04. Viridian Therapeutics, Inc. has a 52-week low of $9.90 and a 52-week high of $27.20.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported ($0.87) earnings per share for the quarter, beating analysts' consensus estimates of ($0.95) by $0.08. The business had revenue of $0.07 million during the quarter, compared to analyst estimates of $0.16 million. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. The company's revenue for the quarter was up .0% compared to the same quarter last year. As a group, sell-side analysts forecast that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently commented on VRDN shares. Royal Bank of Canada dropped their target price on Viridian Therapeutics from $46.00 to $45.00 and set an "outperform" rating on the stock in a report on Wednesday, May 7th. JMP Securities dropped their price objective on Viridian Therapeutics from $42.00 to $38.00 and set a "market outperform" rating on the stock in a research note on Wednesday, May 7th. The Goldman Sachs Group decreased their target price on Viridian Therapeutics from $31.00 to $27.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. Needham & Company LLC reaffirmed a "buy" rating and set a $36.00 target price on shares of Viridian Therapeutics in a report on Tuesday, May 20th. Finally, HC Wainwright reissued a "buy" rating and issued a $34.00 price target on shares of Viridian Therapeutics in a report on Wednesday, April 23rd. One research analyst has rated the stock with a hold rating and ten have issued a buy rating to the company's stock. Based on data from MarketBeat, Viridian Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $36.70.

Check Out Our Latest Stock Analysis on VRDN

Viridian Therapeutics Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.

See Also

• Five stocks we like better than Viridian Therapeutics
• How to Use the MarketBeat Stock Screener
• Workday Stock Price Implosion: An Automatic Buy for AI Investors
• Find and Profitably Trade Stocks at 52-Week Lows
• MercadoLibre Is Soaring—Should You Wait for a Better Entry?
• Stock Market Holidays 2022-2025 - Here’s When the NYSE and NASDAQ Will be Closed
• Doubt the Market? 3 Stocks to Rideout Fear, Uncertainty and Doubt

Want to see what other hedge funds are holding VRDN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Viridian Therapeutics Right Now?

Before you consider Viridian Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viridian Therapeutics wasn't on the list.

While Viridian Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here